Literature DB >> 36262751

Clinical Significance of Fusobacterium nucleatum and Microsatellite Instability in Evaluating Colorectal Cancer Prognosis.

Qiaoxin Zhang1, Yong Xia1, Yanxuan Xie1, Xiaoyang Jiao2, Mi Zeng2, Zhiqiang Fan2, Xin Li2, Yumeng Yuan2.   

Abstract

Objective: Both genetic and microbial factors play important roles in colorectal cancer (CRC) development. The effects of Fusobacterium nucleatum (F. nucleatum) and microsatellite instability (MSI) on CRC prognosis require more clinical evidence. We aimed to investigate the role of F. nucleatum and MSI as biomarkers in predicting the prognosis of CRC.
Methods: CRC patients in various TNM stages were enrolled. MSI status and F. nucleatum were detected by immunohistochemical staining of formalin-fixed paraffin-embedded (FFPE) specimens. The associations between MSI status and F. nucleatum and clinical parameters were analyzed.
Results: MSI tumors were more frequently observed in the colon than in the rectum. Cancerous tissues had higher levels of F. nucleatum than adjacent noncancerous tissues. There were no significant differences in F. nucleatum abundance in different age, sex, tumor stage, location, and tumor marker groups. MSI status was associated with tumor location and stage. Survival analyses revealed that disease-free survival (DFS) was significantly longer in the F. nucleatum-negative, younger age, and TNM stage I-II groups (p< 0.05), and age, advanced TNM stage (III and IV), and F. nucleatum status were independent factors for poor prognosis. Multivariate Cox regression and receiver operating characteristic (ROC) curve analyses showed that conventional tumor biomarkers of CRC had more prognostic value than F. nucleatum and MSI.
Conclusion: Age, advanced TNM stage, and F. nucleatum positivity were independent factors of poor prognosis, suggesting that F. nucleatum and MSI may contribute to the identification of new strategies for the prevention and treatment of CRC.
© 2022 Xie et al.

Entities:  

Keywords:  Fusobacterium nucleatum; colorectal cancer; factors; microsatellite instability; prognostic

Year:  2022        PMID: 36262751      PMCID: PMC9576466          DOI: 10.2147/CMAR.S382464

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.602


  46 in total

1.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.

Authors:  Kosuke Mima; Reiko Nishihara; Zhi Rong Qian; Yin Cao; Yasutaka Sukawa; Jonathan A Nowak; Juhong Yang; Ruoxu Dou; Yohei Masugi; Mingyang Song; Aleksandar D Kostic; Marios Giannakis; Susan Bullman; Danny A Milner; Hideo Baba; Edward L Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Wendy S Garrett; Curtis Huttenhower; Matthew Meyerson; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino
Journal:  Gut       Date:  2015-08-26       Impact factor: 23.059

2.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin.

Authors:  Mara Roxana Rubinstein; Xiaowei Wang; Wendy Liu; Yujun Hao; Guifang Cai; Yiping W Han
Journal:  Cell Host Microbe       Date:  2013-08-14       Impact factor: 21.023

Review 3.  The multifaceted role of the intestinal microbiota in colon cancer.

Authors:  Thergiory Irrazábal; Antoaneta Belcheva; Stephen E Girardin; Alberto Martin; Dana J Philpott
Journal:  Mol Cell       Date:  2014-04-24       Impact factor: 17.970

4.  Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.

Authors:  Kosuke Mima; Yasutaka Sukawa; Reiko Nishihara; Zhi Rong Qian; Mai Yamauchi; Kentaro Inamura; Sun A Kim; Atsuhiro Masuda; Jonathan A Nowak; Katsuhiko Nosho; Aleksandar D Kostic; Marios Giannakis; Hideo Watanabe; Susan Bullman; Danny A Milner; Curtis C Harris; Edward Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Andrew T Chan; Wendy S Garrett; Curtis Huttenhower; Charles S Fuchs; Shuji Ogino
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

5.  Familial Risk and Heritability of Colorectal Cancer in the Nordic Twin Study of Cancer.

Authors:  Rebecca E Graff; Sören Möller; Michael N Passarelli; John S Witte; Axel Skytthe; Kaare Christensen; Qihua Tan; Hans-Olov Adami; Kamila Czene; Jennifer R Harris; Eero Pukkala; Jaakko Kaprio; Edward L Giovannucci; Lorelei A Mucci; Jacob B Hjelmborg
Journal:  Clin Gastroenterol Hepatol       Date:  2017-01-24       Impact factor: 11.382

6.  A Simple and Novel Fecal Biomarker for Colorectal Cancer: Ratio of Fusobacterium Nucleatum to Probiotics Populations, Based on Their Antagonistic Effect.

Authors:  Songhe Guo; Linfang Li; Banglao Xu; Manghui Li; Qiuyao Zeng; Han Xiao; Ying Xue; Yixian Wu; Yidan Wang; Wanli Liu; Ge Zhang
Journal:  Clin Chem       Date:  2018-06-18       Impact factor: 8.327

7.  Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway.

Authors:  Miki Ito; Shinichi Kanno; Katsuhiko Nosho; Yasutaka Sukawa; Kei Mitsuhashi; Hiroyoshi Kurihara; Hisayoshi Igarashi; Taiga Takahashi; Mami Tachibana; Hiroaki Takahashi; Shinji Yoshii; Toshinao Takenouchi; Tadashi Hasegawa; Kenji Okita; Koichi Hirata; Reo Maruyama; Hiromu Suzuki; Kohzoh Imai; Hiroyuki Yamamoto; Yasuhisa Shinomura
Journal:  Int J Cancer       Date:  2015-03-13       Impact factor: 7.396

Review 8.  Genetic instability in human tumors.

Authors:  Stavroula Raptis; Bharati Bapat
Journal:  EXS       Date:  2006

9.  Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.

Authors:  Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Jeffrey A Meyerhardt; Yoshifumi Baba; Kaori Shima; Jonathan N Glickman; Cristina R Ferrone; Mari Mino-Kenudson; Noriko Tanaka; Glenn Dranoff; Edward L Giovannucci; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

10.  Prognostic Impact of Fusobacterium nucleatum Depends on Combined Tumor Location and Microsatellite Instability Status in Stage II/III Colorectal Cancers Treated with Adjuvant Chemotherapy.

Authors:  Hyeon Jeong Oh; Jung Ho Kim; Jeong Mo Bae; Hyun Jung Kim; Nam-Yun Cho; Gyeong Hoon Kang
Journal:  J Pathol Transl Med       Date:  2018-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.